A new therapy targeting toxic tau proteins in Alzheimer's disease.
Official title: Tau Oligomeric Complex 1 Antibody as a Novel Immuno-Gene Therapy for Tauopathy.
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11039023 · Data updated 2026-11-12
This study is exploring a new way to help people with Alzheimer's and similar conditions by using gene therapy to deliver a special antibody directly into brain cells, aiming to tackle the harmful tau proteins that cause damage.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | September 30, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $431,750 |
| NIH project number | 1R21AG091142-01 |
| Project ID | NIH-11039023 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies.
✕Less likely to help
Patients with non-tauopathies or those not diagnosed with Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates a novel approach to treat tauopathies, including Alzheimer's disease, by using gene therapy to deliver a specific antibody that targets toxic tau proteins. The therapy aims to ensure that the antibody is delivered directly into neurons, where it can effectively neutralize harmful tau oligomers that contribute to neurodegeneration. By utilizing adeno-associated viruses (AAVs) for delivery, the research seeks to improve the specificity and efficiency of treatment compared to existing therapies. Patients may benefit from a targeted intervention that addresses the underlying causes of their condition.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for Alzheimer's disease and related dementias by specifically targeting toxic tau proteins.
How similar studies have gone: Other research has shown promise in targeting tau proteins, but this specific approach using gene therapy is relatively novel.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Kanaan, Nicholas M — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Kanaan, Nicholas M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.